Literature DB >> 33028754

Differential Diagnosis of COVID-19: Importance of Measuring Blood Lymphocytes, Serum Electrolytes, and Olfactory and Taste Functions.

Hiroki Nakanishi1, Motohiko Suzuki1,2, Hiroyoshi Maeda3, Yoshitaka Nakamura4, Yosuke Ikegami5, Yuya Takenaka6, Yusuke Mori1, Takahiro Hasuo7, Chihiro Hasegawa8.   

Abstract

Coronavirus disease 2019 (COVID-19) is associated with various symptoms and changes in hematological and biochemical variables. However, clinical features, which can differentiate COVID-19 from non-COVID-19, are not clear. We therefore examined the key clinical features of COVID-19 and non-COVID-19 patients. This study included 60 COVID-19 patients and 100 non-COVID-19 patients, diagnosed by PCR, and no significant differences in the age and sex were seen between the two groups. The frequencies of fatigue, loose stool, diarrhea, nasal obstruction, olfactory dysfunction, taste dysfunction, underlying hyperlipidemia, and the prescription of angiotensin II receptor blocker (ARB) were significantly higher in COVID-19 patients than those in non-COVID-19 patients. The counts of leucocytes, neutrophils, lymphocytes, eosinophils, monocytes, and basophils and the levels of chloride and calcium in blood of COVID-19 patients were significantly lower than those of non-COVID-19 patients. The frequencies of atypical lymphocytes and the levels of lactate dehydrogenase (LDH) and potassium were significantly higher in COVID-19 than those in non-COVID-19. The C-reactive protein (CRP) level in COVID-19 patients was significantly lower than that in non-COVID-19 patients, when we compared CRP levels among patients with elevated CRP. This study is the first to indicate that electrolyte levels and the frequency of atypical lymphocytes in COVID-19 are significantly different from those in non-COVID-19. Fatigue, loose stool, diarrhea, nasal obstruction, olfactory dysfunction, and taste dysfunction were the key symptoms of COVID-19. Furthermore, hyperlipidemia and ARB may be risk factors of COVID-19. In conclusion, leucocytes, leucocyte fractions, CRP, LDH, and electrolytes are useful indicators for COVID-19 diagnosis.

Entities:  

Keywords:  COVID-19; angiotensin II receptor blocker; atypical lymphocyte; electrolytes; hyperlipidemia

Mesh:

Substances:

Year:  2020        PMID: 33028754     DOI: 10.1620/tjem.252.109

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  12 in total

1.  Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.

Authors:  Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed
Journal:  Chem Senses       Date:  2022-01-01       Impact factor: 3.160

Review 2.  Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.

Authors:  Thomas Struyf; Jonathan J Deeks; Jacqueline Dinnes; Yemisi Takwoingi; Clare Davenport; Mariska Mg Leeflang; René Spijker; Lotty Hooft; Devy Emperador; Julie Domen; Anouk Tans; Stéphanie Janssens; Dakshitha Wickramasinghe; Viktor Lannoy; Sebastiaan R A Horn; Ann Van den Bruel
Journal:  Cochrane Database Syst Rev       Date:  2022-05-20

Review 3.  The Prevalence and Pathophysiology of Chemical Sense Disorder Caused by the Novel Coronavirus.

Authors:  Sareesh Naduvil Narayanan; Pooja Shivappa; Sreeshma Padiyath; Anand Bhaskar; Yan Wa Li; Tarig Hakim Merghani
Journal:  Front Public Health       Date:  2022-06-06

Review 4.  Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome.

Authors:  Olga A Sukocheva; Rebekah Maksoud; Narasimha M Beeraka; SabbaRao V Madhunapantula; Mikhail Sinelnikov; Vladimir N Nikolenko; Margarita E Neganova; Sergey G Klochkov; Mohammad Amjad Kamal; Donald R Staines; Sonya Marshall-Gradisnik
Journal:  J Adv Res       Date:  2021-11-26       Impact factor: 12.822

5.  Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis.

Authors:  Endang Mutiawati; Marhami Fahriani; Sukamto S Mamada; Jonny Karunia Fajar; Andri Frediansyah; Helnida Anggun Maliga; Muhammad Ilmawan; Talha Bin Emran; Youdiil Ophinni; Ichsan Ichsan; Nasrul Musadir; Ali A Rabaan; Kuldeep Dhama; Syahrul Syahrul; Firzan Nainu; Harapan Harapan
Journal:  F1000Res       Date:  2021-01-21

6.  Taste loss as a distinct symptom of COVID-19: A systematic review and meta-analysis.

Authors:  Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed
Journal:  medRxiv       Date:  2021-10-09

7.  Self-reported olfactory and gustatory dysfunction and psychophysical testing in screening for COVID-19: A systematic review and meta-analysis.

Authors:  Minh P Hoang; Phillip Staibano; Tobial McHugh; Doron D Sommer; Kornkiat Snidvongs
Journal:  Int Forum Allergy Rhinol       Date:  2021-12-06       Impact factor: 5.426

8.  [HYPOCHLOREMIA ASSOCIATED WITH A GREATER INCIDENCE OF PNEUMONIA IN CHRONIC HEMODIALYSIS PATIENTS WITH COVID-19: A CENTER'S EXPERIENCE].

Authors:  Francisco Valga; Tania Monzón; Nicanor Vega-Diaz; Sergio Ruiz-Santana; Sara Aladro; Rassoul Diallo-Saavedra; Jose Carlos De la Flor; José Carlos Rodriguez-Perez
Journal:  Nefrologia       Date:  2022-02-11       Impact factor: 2.033

Review 9.  Epidemiology, prognosis and management of potassium disorders in Covid-19.

Authors:  Maryam Noori; Seyed A Nejadghaderi; Mark J M Sullman; Kristin Carson-Chahhoud; Ali-Asghar Kolahi; Saeid Safiri
Journal:  Rev Med Virol       Date:  2021-06-02       Impact factor: 11.043

Review 10.  Exploring the Clinical Utility of Gustatory Dysfunction (GD) as a Triage Symptom Prior to Reverse Transcription Polymerase Chain Reaction (RT-PCR) in the Diagnosis of COVID-19: A Meta-Analysis and Systematic Review.

Authors:  Khang Wen Pang; Sher-Lyn Tham; Li Shia Ng
Journal:  Life (Basel)       Date:  2021-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.